Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

Irfan Vardarli, Michael A Nauck, Lars D Köthe, Carolyn F Deacon, Jens Juul Holst, Anja Schweizer, James E Foley

Dipeptidyl peptidase-4 (DPP-4) inhibitors block the degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. The aim of the present study was to quantitatively assess the incretin effect after treatment with the DPP-4 inhibitor vildagliptin (V) or placebo (P) in patients with type 2 diabetes.
Original languageEnglish
JournalJournal of Clinical Endocrinology and Metabolism
Volume96
Issue number4
Pages (from-to)945-954
Number of pages10
ISSN0021-972X
DOIs
Publication statusPublished - 2011

    Research areas

  • Adamantane, Administration, Oral, Adult, Aged, Blood Glucose, Cross-Over Studies, Diabetes Mellitus, Type 2, Dipeptidyl Peptidase 4, Dipeptidyl-Peptidase IV Inhibitors, Female, Glucose, Humans, Incretins, Injections, Intravenous, Insulin, Male, Middle Aged, Nitriles, Pyrrolidines, Up-Regulation

ID: 38444411